Filing identity and reporting period
Important mismatch: The supplied filing is Oxygen Biotherapeutics, Inc.’s unaudited Form 10-Q for the quarter and six months ended October 31, 2011—not a Tenax Therapeutics filing for 2010 Q2. The summary below reflects the filing text provided.
Business context
Oxygen Biotherapeutics was a development-stage biotechnology company focused on oxygen-delivery products. Its programs included Oxycyte, an investigational product for traumatic brain injury, and topical products including Dermacyte and Wundecyte. Management identified topical products as a nearer-term commercialization focus while continuing Oxycyte development.
Financial performance and liquidity
| Metric | Three months ended Oct. 31, 2011 | Six months ended Oct. 31, 2011 | Comparable 2010 period |
|---|---|---|---|
| Product revenue | $27,415 | $86,892 | $36,083; $42,981 |
| Government grant revenue | $78,244 | $78,244 | $0 |
| Total net revenue | $95,159 | $120,032 | $27,126; $32,236 |
| Operating expenses | $2.149 million | $4.602 million | $2.084 million; $5.112 million |
| Net loss | $2.930 million | $5.799 million | $2.052 million; $5.054 million |
| Basic net loss per share | $0.12 | $0.25 | $0.09; $0.22 |
Product revenue fell 24% year over year in the quarter, which management attributed partly to reduced direct selling, and rose 102% for the six-month period, helped by distributor shipments to Mexico. Management reported product gross margins of 62% for the quarter and 48% for the six months, versus 75% in the comparable 2010 periods, citing product mix and distributor sales.
At October 31, 2011, cash was $2.004 million, current assets $2.874 million, and current liabilities $2.096 million, yielding working capital of $777,617. Total liabilities were $8.274 million; notes payable, net, were approximately $6.186 million. Stockholders’ deficit was $3.726 million. For the six months, operating cash use was $4.583 million, investing cash use $161,475, and financing cash inflow $5.797 million; cash increased by $1.052 million.
Changes versus prior periods and financing
Six-month net loss increased about 15% despite operating expenses declining 10%, primarily because interest expense rose to $1.308 million from $6,589. The increase reflected accretion on Vatea notes and amortization of discounts and costs on the June 2011 convertible notes. The company raised approximately $4.9 million through those notes, which bear 15% annual interest, mature in 2014, and are convertible at $2.255 per share; related warrants and conversion features created substantial noncash debt discounts and potential dilution.
After quarter-end, the company received $8 million in a November 2011 share sale and used the proceeds to repay the Vatea notes, including the unaccreted final-payment premium. A December 2011 registered offering initially closed for $3.5 million; a further installment of up to $4 million was conditional. Management stated that cash, including proceeds from subsequent financing, was expected to fund operations through July 31, 2012.
Outlook, risks, and unusual items
- The filing states substantial doubt about the company’s ability to continue as a going concern: it had a $97.7 million accumulated deficit, required substantial additional funding, and had no assurance financing would be available. The financial statements contain no going-concern adjustments.
- Management expected ongoing losses and substantial future research, clinical-trial, regulatory, and commercialization costs. It stated that operations beyond July 31, 2012 depended on license income or outside financing.
- Oxycyte’s U.S. Phase II study remained on FDA clinical hold pending responses to safety concerns; a Phase II-b study was underway in Switzerland and Israel. The company also had a $2.07 million U.S. Army cost-reimbursement award for Oxycyte safety studies.
- The Tenor funds sued over an alleged breach of a right of first offer in connection with the June 2011 financing. Discovery was underway; the company disputed the claim and had not accrued a liability.
- The company had accrued approximately $550,000 for potential Section 409A-related payroll taxes, interest, and penalties; management estimated possible adverse outcomes could exceed the recorded amount by approximately $500,000.
- The December preferred-stock financing carried potential dilution, restrictive covenants, and significant default penalties. The second installment was conditional, creating additional funding risk.
- Management reported effective disclosure controls as of October 31, 2011. It also described governance and control enhancements following an Audit Committee investigation disclosed in the prior quarterly report.
Most important facts for investors to verify
- Confirm that this Oxygen Biotherapeutics filing—not a Tenax Therapeutics filing—is the intended source and reporting period.
- Verify current cash runway and whether the conditional second installment of the December financing closed, along with any subsequent capital raises.
- Review the terms, repayment status, conversion dilution, and warrant overhang associated with the notes and preferred-stock financings.
- Track Oxycyte’s FDA clinical hold, overseas Phase II-b trial progress, and the regulatory and commercial path for Dermacyte and Wundecyte.
- Monitor the Tenor litigation and potential Section 409A exposure, including any changes to accrued contingencies.